Detailed view for LmjF.17.1400
Basic information
TDR Targets ID: 23729
Leishmania major, otubain, putative,otubain cysteine peptidase, Clan CA, family C65, putative
Source Database / ID: TriTrypDB GeneDB
Leishmania major, otubain, putative,otubain cysteine peptidase, Clan CA, family C65, putative
Source Database / ID: TriTrypDB GeneDB
pI: 4.3723 |
Length (AA): 270 |
MW (Da): 30181 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Network
Pfam domains
PF10275
Peptidase C65 Otubain
Gene Ontology
Mouse over links to read term descriptions.
GO:0016579
protein deubiquitination GO:0016787 hydrolase activity
Metabolic Pathways
This gene is not mapped to any metabolic pathway in KEGG.
Structural information
Modbase 3D models:
There are 6 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
| Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
|---|---|---|---|---|---|---|---|---|---|
| 26 | 269 | 1tff (A) | 8 | 232 | 22.00 | 0 | 1 | 1.03 | -1 |
| 69 | 265 | 1tff (A) | 39 | 228 | 27.00 | 0.0000000000063 | 1 | 1.1 | -1.22 |
| 7 | 267 | 4ddg (A) | 1027 | 1271 | 32.00 | 0 | 1 | 1.31437 | -0.16 |
| 7 | 268 | 4ldt (A) | 23 | 274 | 28.00 | 0 | 1 | 1.30607 | -0.34 |
| 25 | 267 | 2zfy (A) | 46 | 271 | 34.00 | 0 | 1 | 1.2826 | -0.79 |
| 95 | 156 | 1o1z (A) | 32 | 91 | 38.00 | 0.4 | 0.43 | 0.61423 | 0.01 |
Help me make sense of these data.
Target Beg: first modeled residue
Target End: last modeled residue
Template: template structure used for modelling (PDB accession and chain)
Template Beg: first template residue in target-template alignment
Template End: last template residue in target-template alignment
Identity: sequence identity
Evalue: E value for target-template hit
Model Score: GA341 score (>0.7 for reliable model)
MPQS: ModPipe Quality Score (>1.1 for reliable model)
zDope: zDope Score (negative for reliable model)
Target End: last modeled residue
Template: template structure used for modelling (PDB accession and chain)
Template Beg: first template residue in target-template alignment
Template End: last template residue in target-template alignment
Identity: sequence identity
Evalue: E value for target-template hit
Model Score: GA341 score (>0.7 for reliable model)
MPQS: ModPipe Quality Score (>1.1 for reliable model)
zDope: zDope Score (negative for reliable model)
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
No structure availble in the PDB for this protein
Expression
| Upregulation Percent | Ranking | Stage | Dataset |
|---|---|---|---|
| Upper 80-100% percentile | amastigotes, metacyclic. | Fernandes MC |
-
Fernandes MC Dual Transcriptome Profiling of Leishmania-Infected Human Macrophages Reveals Distinct Reprogramming Signatures.
Orthologs
Ortholog group members (OG5_128982)
| Species | Accession | Gene Product |
|---|---|---|
| Arabidopsis thaliana | AT1G28120 | ubiquitin thioesterase otubain-like protein |
| Caenorhabditis elegans | CELE_C25D7.8 | Protein OTUB-1 |
| Drosophila melanogaster | Dmel_CG4968 | CG4968 gene product from transcript CG4968-RA |
| Echinococcus granulosus | EgrG_000540000 | Ubiquitin thioesterase otubain protein |
| Echinococcus multilocularis | EmuJ_000540000 | Ubiquitin thioesterase otubain protein |
| Homo sapiens | ENSG00000167770 | OTU deubiquitinase, ubiquitin aldehyde binding 1 |
| Homo sapiens | ENSG00000089723 | OTU deubiquitinase, ubiquitin aldehyde binding 2 |
| Leishmania braziliensis | LbrM.17.1540 | otubain, putative,otubain cysteine peptidase, Clan CA, family C65, putative |
| Leishmania donovani | LdBPK_171520.1 | otubain cysteine peptidase, Clan CA, family C65, putative |
| Leishmania infantum | LinJ.17.1520 | otubain, putative,otubain cysteine peptidase, Clan CA, family C65, putative |
| Leishmania major | LmjF.17.1400 | otubain, putative,otubain cysteine peptidase, Clan CA, family C65, putative |
| Leishmania mexicana | LmxM.17.1400 | otubain, putative,otubain cysteine peptidase, Clan CA, family C65, putative |
| Loa Loa (eye worm) | LOAG_04168 | hypothetical protein |
| Mus musculus | ENSMUSG00000024767 | OTU domain, ubiquitin aldehyde binding 1 |
| Mus musculus | ENSMUSG00000021203 | OTU domain, ubiquitin aldehyde binding 2 |
| Neospora caninum | NCLIV_026530 | ubiquitin thiolesterase protein, putative |
| Oryza sativa | 4346169 | Os08g0537800 |
| Schistosoma japonicum | Sjp_0303940 | ko:K09602 ubiquitin thioesterase protein OTUB1, putative |
| Schistosoma mansoni | Smp_097810.2 | otubain-1 (C65 family) |
| Schmidtea mediterranea | mk4.008804.00 | |
| Schmidtea mediterranea | mk4.020692.00 | Ubiquitin thioesterase otubain-like |
| Trypanosoma brucei gambiense | Tbg972.5.3790 | otubain, putative,otubain cysteine peptidase, Clan CA, family C65, putative |
| Trypanosoma brucei | Tb927.5.2700 | otubain cysteine peptidase, Clan CA, family C65, putative |
| Trypanosoma congolense | TcIL3000_5_2790 | otubain cysteine peptidase, Clan CA, family C65, putative |
| Trypanosoma cruzi | TcCLB.507047.110 | otubain cysteine peptidase, Clan CA, family C65, putative |
| Trypanosoma cruzi | TcCLB.509179.150 | otubain cysteine peptidase, Clan CA, family C65, putative |
| Toxoplasma gondii | TGME49_260510 | ubiquitin thioesterase otubain-like family protein |
Essentiality
LmjF.17.1400 has one or more orthologs with essentiality data
| Gene/Ortholog | Organism | Phenotype | Source Study |
|---|---|---|---|
| Tb927.5.2700 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
| Tb927.5.2700 | Trypanosoma brucei | significant gain of fitness in bloodstream forms (6 days) | alsford |
| Tb927.5.2700 | Trypanosoma brucei | significant gain of fitness in procyclic forms | alsford |
| Tb927.5.2700 | Trypanosoma brucei | significant gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
| TGME49_260510 | Toxoplasma gondii | Probably non-essential | sidik |
-
yeastgenome Systematic deletion of yeast genes Saccharomyces Genome Database -
wormbase C. elegans RNAi experiments WormBase web site, http://www.wormbase.org, release WS170 -
shigen Profiling of E. coli Chromosome (PEC) National Institute of Genetics, Japan -
neb C. elegans RNAi phenotypes Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs -
keio Systematic single-gene knock-out mutants of E. coli K12 The Keio Collection -
alsford High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome Genome Res 2011, 21:915-924 -
nmpdr Genome-scale essentiality datasets from published studies (M. tuberculosis) National Microbial Pathogen Data Resource -
gerdes Experimental determination and system-level analysis of essential genes in E. coli MG1655 Gerdes et al., J Bacteriol. 2003 185:5673-84 -
blattner Systematic mutagenesis of the E. coli (MG1655) genome J Bacteriol 2004, 186:4921-4930
Phenotypes and Validation (curated)
Annotated phenotypes:
| Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
|---|---|---|---|---|---|---|
| growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | amastigote (BTO:0000062) | inferred from bioassay (ECO:0000094) | Leishmania mexicana | 337527 561727 585910 |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 4174-73-6. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in cell assay; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. | References: | 7179420 | |
| growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania mexicana | 337527 561727 585910 |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 4174-73-6. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in cell assay; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. | References: | 7179420 | |
| catalytic activity (GO:0003824) | decreased (PATO:0000468) | in vitro (MI:0492) | inferred from enzyme assay (ECO:0000005) | Leishmania mexicana | 337527 561727 585910 | |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 4174-73-6. chemical inhibition with known cysteine peptidase inhibitors leads to reduced enzyme activity in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. | References: | 7179420 | |
| growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | amastigote (BTO:0000062) | inferred from bioassay (ECO:0000094) | Leishmania amazonensis | No drug identifiers listed for this gene. |
| Annotator: | aaronjr@u.washington.edu. | Comment: | L-Amino acid esters appear to be hydrolyzed by cysteine peptidase and lead to slow growth of Leishmania sp. in cell assay; . | References: | 1428504 2235078 2345655 | |
| growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | amastigote (BTO:0000062) | inferred from bioassay (ECO:0000094) | Leishmania mexicana | No drug identifiers listed for this gene. |
| Annotator: | aaronjr@u.washington.edu. | Comment: | chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in cell assay; . | References: | 2270108 | |
| catalytic activity (GO:0003824) | decreased (PATO:0000468) | in vitro (MI:0492) | inferred from enzyme assay (ECO:0000005) | Leishmania amazonensis | 81384 576750 | |
| Annotator: | aaronjr@u.washington.edu. | Comment: | chemical inhibition with known cysteine peptidase inhibitors leads to reduced enzyme activity in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. | References: | 8023752 | |
| catalytic activity (GO:0003824) | decreased (PATO:0000468) | in vitro (MI:0492) | inferred from enzyme assay (ECO:0000005) | Leishmania major | 81384 576750 | |
| Annotator: | aaronjr@u.washington.edu. | Comment: | chemical inhibition with known cysteine peptidase inhibitors leads to reduced enzyme activity in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. | References: | 8023752 | |
| growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | amastigote (BTO:0000062) | host (GO:0018995) | Leishmania donovani | No drug identifiers listed for this gene. |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 81989-95-9. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in vivo (balb/c mouse) and cure of parasite burden; also provided protection against further infection (partial vaccine); General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. | References: | 11238649 | |
| growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | amastigote (BTO:0000062) | inferred from bioassay (ECO:0000094) | Leishmania donovani | No drug identifiers listed for this gene. |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 81989-95-9. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in vivo (balb/c mouse) and cure of parasite burden; also provided protection against further infection (partial vaccine); General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. | References: | 11238649 | |
| growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | amastigote (BTO:0000062) | host (GO:0018995) | Leishmania tropica | No drug identifiers listed for this gene. |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 233277-99-1. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in vivo (balb/c mouse lesions) and reduced lesion size; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. | References: | 15172223 | |
| growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | amastigote (BTO:0000062) | inferred from bioassay (ECO:0000094) | Leishmania tropica | No drug identifiers listed for this gene. |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 233277-99-1. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in vivo (balb/c mouse lesions) and reduced lesion size; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. | References: | 15172223 | |
| growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania tropica | No drug identifiers listed for this gene. |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 233277-99-1. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in cell assay; inhibitors overcome redundancy?; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. | References: | 15172223 | |
| growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania donovani | 0 6693 81384 236103 327961 376038 543486 543487 575389 575390 575391 576750 |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 22386-37-4; Drug: 36677-78-8; Drug: 52090-11-6; Drug: 98319-30-3; Drug: 300670-24-0; Drug: 302939-54-4; Drug: 303216-44-6; Drug: 309742-24-3; Drug: 312280-89-0; Drug: 315703-20-9; Drug: 320369-30-0; Drug: 322409-94-9; Drug: 330220-86-5; Drug: 335206-77-4; Drug: 347910-28-5; Drug: 352560-86-2; Drug: 363180-61-4; Drug: 413580-11-7; Drug: 416878-80-3; Drug: 419547-26-5; Drug: 428852-79-3; Drug: 825612-08-6; Drug: 825612-09-7; Drug: 825612-10-0. in silico virtual screening of falcipains lead to bioactive compounds against Leishmania promastigotes; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. | References: | 15588096 | |
| catalytic activity (GO:0003824) | decreased (PATO:0000468) | in vitro (MI:0492) | inferred from in-silico analysis (ECO:0000043) | Leishmania donovani | 0 6693 81384 236103 327961 376038 543486 543487 575389 575390 575391 576750 | |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 22386-37-4; Drug: 36677-78-8; Drug: 52090-11-6; Drug: 98319-30-3; Drug: 300670-24-0; Drug: 302939-54-4; Drug: 303216-44-6; Drug: 309742-24-3; Drug: 312280-89-0; Drug: 315703-20-9; Drug: 320369-30-0; Drug: 322409-94-9; Drug: 330220-86-5; Drug: 335206-77-4; Drug: 347910-28-5; Drug: 352560-86-2; Drug: 363180-61-4; Drug: 413580-11-7; Drug: 416878-80-3; Drug: 419547-26-5; Drug: 428852-79-3; Drug: 825612-08-6; Drug: 825612-09-7; Drug: 825612-10-0. in silico virtual screening of falcipains lead to bioactive compounds against cysteine protease in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. | References: | 15588096 | |
| catalytic activity (GO:0003824) | decreased (PATO:0000468) | in vitro (MI:0492) | inferred from specific protein inhibition (ECO:0000020) | Leishmania donovani | 0 6693 81384 236103 327961 376038 543486 543487 575389 575390 575391 576750 | |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 22386-37-4; Drug: 36677-78-8; Drug: 52090-11-6; Drug: 98319-30-3; Drug: 300670-24-0; Drug: 302939-54-4; Drug: 303216-44-6; Drug: 309742-24-3; Drug: 312280-89-0; Drug: 315703-20-9; Drug: 320369-30-0; Drug: 322409-94-9; Drug: 330220-86-5; Drug: 335206-77-4; Drug: 347910-28-5; Drug: 352560-86-2; Drug: 363180-61-4; Drug: 413580-11-7; Drug: 416878-80-3; Drug: 419547-26-5; Drug: 428852-79-3; Drug: 825612-08-6; Drug: 825612-09-7; Drug: 825612-10-0. in silico virtual screening of falcipains lead to bioactive compounds against cysteine protease in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. | References: | 15588096 | |
| growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania donovani | No drug identifiers listed for this gene. |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 2935-91-3; Drug: 24117-97-3; Drug: 98647-23-5; Drug: 198124-18-4; Drug: 256238-87-6; Drug: 257287-52-8; Drug: 263157-80-8; Drug: 294854-43-6; Drug: 303124-84-7; Drug: 303147-38-8; Drug: 321579-84-4; Drug: 331247-87-1; Drug: 337923-53-2; Drug: 338791-39-2; Drug: 675828-74-7; Drug: 676226-56-5; Drug: 678967-57-2; Drug: 681213-40-1; Drug: 686272-33-3; Drug: 696586-43-3; Drug: 705250-31-3; Drug: 708987-83-1; Drug: 831234-40-3; Drug: 882161-95-7; Drug: 882161-98-0; Drug: 882161-99-1; Drug: 882162-00-7; Drug: 882162-01-8; Drug: 882162-02-9; Drug: 882162-03-0; Drug: 882162-04-1; Drug: 882162-05-2; Drug: 882162-06-3; Drug: 882162-07-4; Drug: 882162-08-5; Drug: 882162-09-6; Drug: 882162-10-9; Drug: 882162-11-0; Drug: 882162-12-1; Drug: 882162-13-2; Drug: 882162-14-3. in silico virtual screening of falcipains lead to bioactive compounds against Leishmania promastigotes; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. | References: | 16509575 | |
| catalytic activity (GO:0003824) | decreased (PATO:0000468) | in vitro (MI:0492) | inferred from in-silico analysis (ECO:0000043) | Leishmania donovani | No drug identifiers listed for this gene. | |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 2935-91-3; Drug: 24117-97-3; Drug: 98647-23-5; Drug: 198124-18-4; Drug: 256238-87-6; Drug: 257287-52-8; Drug: 263157-80-8; Drug: 294854-43-6; Drug: 303124-84-7; Drug: 303147-38-8; Drug: 321579-84-4; Drug: 331247-87-1; Drug: 337923-53-2; Drug: 338791-39-2; Drug: 675828-74-7; Drug: 676226-56-5; Drug: 678967-57-2; Drug: 681213-40-1; Drug: 686272-33-3; Drug: 696586-43-3; Drug: 705250-31-3; Drug: 708987-83-1; Drug: 831234-40-3; Drug: 882161-95-7; Drug: 882161-98-0; Drug: 882161-99-1; Drug: 882162-00-7; Drug: 882162-01-8; Drug: 882162-02-9; Drug: 882162-03-0; Drug: 882162-04-1; Drug: 882162-05-2; Drug: 882162-06-3; Drug: 882162-07-4; Drug: 882162-08-5; Drug: 882162-09-6; Drug: 882162-10-9; Drug: 882162-11-0; Drug: 882162-12-1; Drug: 882162-13-2; Drug: 882162-14-3. in silico virtual screening of falcipains lead to bioactive compounds against cysteine protease in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. | References: | 16509575 | |
| catalytic activity (GO:0003824) | decreased (PATO:0000468) | in vitro (MI:0492) | inferred from specific protein inhibition (ECO:0000020) | Leishmania donovani | No drug identifiers listed for this gene. | |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 2935-91-3; Drug: 24117-97-3; Drug: 98647-23-5; Drug: 198124-18-4; Drug: 256238-87-6; Drug: 257287-52-8; Drug: 263157-80-8; Drug: 294854-43-6; Drug: 303124-84-7; Drug: 303147-38-8; Drug: 321579-84-4; Drug: 331247-87-1; Drug: 337923-53-2; Drug: 338791-39-2; Drug: 675828-74-7; Drug: 676226-56-5; Drug: 678967-57-2; Drug: 681213-40-1; Drug: 686272-33-3; Drug: 696586-43-3; Drug: 705250-31-3; Drug: 708987-83-1; Drug: 831234-40-3; Drug: 882161-95-7; Drug: 882161-98-0; Drug: 882161-99-1; Drug: 882162-00-7; Drug: 882162-01-8; Drug: 882162-02-9; Drug: 882162-03-0; Drug: 882162-04-1; Drug: 882162-05-2; Drug: 882162-06-3; Drug: 882162-07-4; Drug: 882162-08-5; Drug: 882162-09-6; Drug: 882162-10-9; Drug: 882162-11-0; Drug: 882162-12-1; Drug: 882162-13-2; Drug: 882162-14-3. in silico virtual screening of falcipains lead to bioactive compounds against cysteine protease in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. | References: | 16509575 | |
| growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania major | No drug identifiers listed for this gene. |
| Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 872361-01-8; Drug: 872361-02-9; Drug: 886061-72-9; Drug: 886061-73-0; Drug: 886061-74-1; Drug: 886061-75-2; Drug: 886061-76-3; Drug: 886061-77-4; Drug: 886061-78-5; Drug: 886061-79-6; Drug: 886061-80-9; Drug: 886061-81-0; Drug: 886061-82-1; Drug: 886061-85-4; Drug: 886061-86-5; Drug: 886061-87-6; Drug: 886061-88-7; Drug: 886061-89-8; Drug: 886061-90-1; Drug: 886061-91-2; Drug: 886061-92-3; Drug: 886061-93-4; Drug: 886061-99-0; Drug: 886062-00-6; Drug: 886062-05-1; Drug: 886062-06-2; Drug: 886062-07-3; Drug: 886062-08-4; Drug: 886062-09-5; Drug: 886062-10-8; Drug: 886062-11-9; Drug: 886062-12-0; Drug: 886062-13-1; Drug: 886062-14-2; Drug: 886062-15-3; Drug: 886062-16-4; Drug: 886062-17-5; Drug: 906674-95-1. chemical inhibition with peptidomimetics and Aziridine-2,3-dicarboxylates leads to slow growth of Leishmania sp. in cell assay; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. | References: | 16801424 | |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Annotated validation
- Validation: inhibited in cell-free system
- annotated by: aaronjr@u.washington.edu.
- References: 15588096 16509575 7179420 8023752
Associated compounds / Druggability
Known modulators for this target
| Compound | Source | Reference |
|---|---|---|
| Curated by TDRTargets | References | |
| Curated by TDRTargets | References | |
| Curated by TDRTargets | References | |
| Curated by TDRTargets | References | |
| Curated by TDRTargets | References | |
| Curated by TDRTargets | References | |
| Curated by TDRTargets | References | |
| Curated by TDRTargets | References | |
| Curated by TDRTargets | References | |
| Curated by TDRTargets | References | |
| Curated by TDRTargets | References | |
| Curated by TDRTargets | References | |
| Curated by TDRTargets | References | |
| Curated by TDRTargets | References |
Predicted associations
By orthology with druggable targets
Non orthologous druggable targets
By sequence similarity to non orthologous druggable targets
No additional associated druggable targets
Obtained from network model
No druggable targets predicted through repurposing network model
Assayability
Assay information
No assay information for this target.
Reagent availability
No reagent availability information for this target.
Bibliographic References
11 literature references were collected for this gene.
If you have references for this gene, please enter them in a user comment (below) or Contact us.
User comments
No user comments are available for this gene.
Log in to add comments, or register.